Recombinant human IL-11 protein - Bioactive cytokine

Recombinant cytokine, source: CHO cells

ABOUT

Human IL-11 protein - Mammalian cell-expressed, tag-free, carrier-free

Recombinant human IL-11 is a high-quality and biologically active cytokine, validated using proprietary IL-11 reporter cells (see figure). This gp130 cytokine receptor family member is produced in CHO cells to ensure protein glycosylation and bona fide 3D structure.

Recombinant human IL-11 can be used together with HEK-Blue™ IL-11 cells for the screening of inhibitory molecules, such as therapeutic monoclonal antibodies targeting the IL-11 signaling pathway.

 

Key features

  • Each lot is validated using HEK-Blue™ IL-11 cells
  • Endotoxin ≤ 0.1 EU/µg
  • 0.2 µm sterile-filtered

Applications

  • Standard for IL-11 detection and quantification
  • Screening and release assays for antibodies blocking IL-11 signaling
  • Screening and release assays for engineered IL-11

 

Interleukin-11 (IL-11) is a member of the IL-6-type cytokine family, known for its diverse roles in hematopoiesis, bone remodeling, and modulation of inflammatory responses. It is upregulated in a variety of fibro-inflammatory diseases such as systemic sclerosis, rheumatoid arthritis, pulmonary fibrosis, and inflammatory bowel disease. Moreover, IL-11 has emerged as a potential therapeutic target in fibrotic diseases and certain cancers.

More details

All InvivoGen products are for internal research use only, and not for human or veterinary use.

Signaling pathway in HEK-Blue™ IL-11 cells
Signaling pathway in HEK-Blue™ IL-11 cells

SPECIFICATIONS

Specifications

Source
CHO cells
Species
Human
Accession sequence

P20809-1

Protein size
178 a.a. (P22-L199)
Molecular weight
~ 18 kDa (SDS-PAGE)
Carrier
Carrier-free
Tag
Tag-free
Purity
≥ 95% (SDS-PAGE)
Solubility

100 μg/ml in water

Formulation buffer

Phosphate buffer saline (pH 7.4), 5% saccharose

Appearance (form)
Lyophilized
Reconstitution buffer
Endotoxin-free water (provided)
Sterility

0.2 µm filtration

Endotoxin

The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.

Applications

Cellular assays (tested), ELISA

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Recombinant human IL-11
  • Cat code: 
    rcyc-hil11
  • Quantity: 
    10 µg
Includes:

1.5 ml endotoxin-free water

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: -20°C for up to 6 months

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Interleukin 11 background

Interleukin‑11 (IL‑11) belongs to the IL‑6 cytokine family, which includes Oncostatin M (OSM), IL‑6, ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), cardiotrophin‑1 (CT‑1), IL‑31, and IL‑27. These cytokines primarily function by binding to specific alpha receptors - sometimes shared among family members - which then associate with the common gp130 co-receptor to trigger intracellular signaling, mainly through the canonical JAK/STAT pathway [1].

While IL‑11 was traditionally regarded as anti-fibrotic, anti-inflammatory, and pro-regenerative, recent studies have challenged this view. Newer studies highlight IL‑11 as a driver of fibrosis, inflammation, and impaired tissue regeneration [1,2].

The profibrotic role of IL‑11 was first identified in 2017 by Schafer and colleagues, who demonstrated that IL-11 mediates the pro-fibrotic effect of TGF-β1, the prototypic profibrotic cytokine [3-4]. Now, IL‑11 is recognized as a key downstream mediator of TGF‑β signaling, promoting fibrosis through ERK pathway activation in stromal cells. This profibrotic activity is implicated in a range of disorders, including pulmonary, cardiac, and hepatic fibrosis [3]. These discoveries have made IL‑11 a promising therapeutic target for fibrotic diseases, with the potential to halt or even reverse tissue fibrosis. Therapeutic approaches under investigation include monoclonal antibodies directed against IL‑11 itself or its receptor [3].

Moreover, IL‑11 has also emerged as a key player in cancer biology, particularly in shaping the tumor microenvironment. Targeting IL‑11 or its receptor may not only limit fibrotic remodeling but also improve anti-tumor immune responses, particularly in combination with immune checkpoint inhibitors like anti‑PD‑1 antibody [1,5]. These advances highlight IL‑11 as a compelling candidate for therapeutic intervention in both fibrotic and oncologic settings.

 

References:

1. Cook SA., 2023. Understanding interleukin 11 as a disease gene and therapeutic target. Biochem J.480(23):1987-2008.
2. Fung KY, et al., 2022. Emerging roles for IL-11 in inflammatory diseases. Cytokine. 149:155750.
3. O'Reilly S., 2023. Interleukin-11 and its eminent role in tissue fibrosis: a possible therapeutic target. Clin Exp Immunol. 214(2):154-161.
4. Schafer S, et al., 2017. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature. 552(7683):110-115.
5. Zhang C, et al. 2025. IL-11/IL-11R signal inhibition by 9MW3811 remodels the immune tumor microenvironment and enhances anti-tumor efficacy of PD-1 blockade. NPJ Precis Oncol. 9(1):138. 

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?